With interest in wellness rising rapidly across the insurance industry, a research collaboration between RGA and the University of Leicester seeks to provide critical insights to enhance underwriting and pricing for wellness products, as well as to inform consumers on ways to improve their health and longevity.
Decades of research have demonstrated how individual health conditions and behaviors impact morbidity and mortality. When underwriting life and health insurance, however, determining how multiple wellness and lifestyle rating factors and comorbidities interact and affect one another remains challenging.
Mortality and morbidity trends among hospitalized COVID-19 survivors can shed vital light into the insurance implications of the pandemic.
Understanding the effects of physical activity on mortality and morbidity risk
Critically important containment measures have been shown to ‘flatten the curve’ of new SARS-CoV-2 infections, save lives and ease the pressure on healthcare systems and medical supplies. At the same time, there are indications that these and other COVID-19 related measures will, depending on their extent and duration, also impact on the future mortality and morbidity trends of other areas of disease and health.
This paper seeks to understand the unique set of circumstances that led to the dramatic rise in opioid prescriptions over the last few decades, and provide a brief overview of the resultant morbidity and mortality for the insured population.
RGA’s Dr. Daniel Zimmerman answers questions on sepsis development and mortality trends.
From the end of the 2000s, after the introduction of the first antiretroviral therapies (ART), it became clear that the benefits of these treatments were considerably greater than their side effects, especially when introduced early. The recommendation at present is to begin treatment with ART as soon as CD4 T-cell count falls below the normal level of 500/mm3.
This article is intended to provide essential background information on the Zika virus in order to assist insurers’ understanding and risk assessment of the situation. Insurers must continually stay abreast of these risks and rapidly assess the potential impact on morbidity and mortality – often with only preliminary scientific or actuarial data.
At the present time, in the world mental illness represents the 5th leading cause of mortality and disability and the 3rd leading cause of sick leave and invalidity. 400 million people are affected by mental or neurological disorders, or suffer from psychosocial problems.